[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336337-105":59,"doc-detail-336337-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","development-of-225ac-doped-biocompatible-nanoparticles-for-targeted-alpha-therapy","Development of 225Ac-doped Biocompatible Nanoparticles for Targeted Alpha Therapy","","Targeted alpha therapy (TAT) uses chemical affinity or active targeting, commonly via radioimmunoconjugates, to deliver alpha-emitting radionuclides to cancerous tissue. However, transmetalation by competing ions and recoil-driven bond breaking from decay daughters can reduce retention of radionuclides and alter the dose delivered to tumor cells. Encapsulating alpha emitters in nanoparticles can mitigate these issues. This study uses PLGA nanoparticles to encapsulate and retain actinium-225, improving delivery to breast cancer cells and increasing cell death compared with free 225Ac3+.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-of-225ac-doped-biocompatible-nanoparticles-for-targeted-alpha-therapy/336337/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-of-225ac-doped-biocompatible-nanoparticles-for-targeted-alpha-therapy/336337.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is targeted alpha therapy (TAT) and how does it work?","Question",{"text":113,"@type":114},"TAT delivers alpha-emitting radionuclides to cancer tissue through chemical affinity or active targeting. High local energy deposition within a short tissue range enables precise treatment.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What main challenges affect TAT performance in vivo?",{"text":118,"@type":114},"Competing ions can cause transmetalation of the parent radionuclide, and decay daughters can relocate due to bond-breaking recoil energy. These processes influence radionuclide retention and the effective dose to cancer cells.",{"name":120,"@type":111,"acceptedAnswer":121},"How did PLGA nanoparticles change delivery of actinium-225 in this study?",{"text":122,"@type":114},"PLGA encapsulation of [225Ac]Ac3+ and the chelated [225Ac]AcBLPhen reduced release and increased delivery to murine and human breast cancer cells. This led to higher cell death than free [225Ac]Ac3+ in solution.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},336337,1790384488,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Toro‑González et al.  \nJournal of Nanobiotechnology [https://doi.org/10.1186/s12951](https://doi.org/10.1186/s12951)  \n(2024) 22:306 ‑024‑02520‑6  \nJournal of Nanobiotechnology  \n RESEARCH Open Access  \nDevelopment of 225Ac‑doped biocompatible   nanoparticles for targeted alpha therapy  \nMiguel Toro-González1, Ngozi Akingbesote1,2, Amber Bible3, Debjani Pal 1, Brian Sanders3, Alexander S. Ivanov4, Santa Jansone-Popova4, Ilja Popovs4, Paul Benny1, Rachel Perry2 and Sandra Davern 1*  \nAbstract  \nTargeted alpha therapy (TAT) relies on chemical affinity or active targeting using radioimmunoconjugates as strategies to deliver α-emitting radionuclides to cancerous tissue. These strategies can be affected by transmetalation of the parent radionuclide by competing ions in vivo and the bond-breaking recoil energy of decay daughters. The retention of α-emitting radionuclides and the dose delivered to cancer cells are influenced by these processes. Encapsulating α-emitting radionuclides within nanoparticles can help overcome many of these challenges. Poly(lactic-coglycolic acid) (PLGA) nanoparticles are a biodegradable and biocompatible delivery platform that has been used for drug delivery. In this study, PLGA nanoparticles are utilized for encapsulation and retention of actinium-225 ([225Ac] Ac3+ ) . Encapsulation of [225Ac]Ac3+ within PLGA nanoparticles (Zave = 155.3 nm) was achieved by adapting a doubleemulsion solvent evaporation method. The encapsulation efficiency was affected by both the solvent conditions and the chelation of [225Ac]Ac3+ . Chelation of [225Ac]Ac3+ to a lipophilic 2,9-bis-lactam-1,10-phenanthroline ligand ([225Ac]AcBLPhen) significantly decreased its release (\u003C 2%) and that of its decay daughters (\u003C 50%) from PLGA nanoparticles. PLGA nanoparticles encapsulating [225Ac]AcBLPhen significantly increased the delivery of [225Ac]Ac3+ to murine (E0771) and human (MCF-7 and MDA-MB-231) breast cancer cells with a concomitant increase in cell death over free [225Ac]Ac3+ in solution. These results demonstrate that PLGA nanoparticles have potential as radionuclide delivery platforms forTAT to advance precision radiotherapy for cancer. In addition, this technology offers an alternative use for ligands with poor aqueous solubility, low stability, or low affinity, allowing them to be repurposed forTAT by encapsulation within PLGA nanoparticles.  \nKeywords Actinium-225, Poly(lactic-co-glycolic acid), Nanoparticles, Therapy, Ligand  \n*Correspondence: Sandra Davern [davernsm@ornl.gov](davernsm@ornl.gov)  \nFull list of author information is available at the end of the article  \n© UT-Battelle, LLC 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[. The Creative Commons Public Domain Dedication waiver (](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[http://creativeco](http://creativeco)[mmons.org/publicdomain/zero/1.0/](mmons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data.  \nToro‑González etal. Journal ","cbCaiutRbvGWXwOM","https://ap.wps.com/l/cbCaiutRbvGWXwOM","pdf",4213794,17,"English","# Abstract\n# Keywords\n# Introduction\n## Targeted alpha therapy overview\n## Targeting strategies and challenges\n## Nanoparticle encapsulation approach","[{\"question\":\"What is targeted alpha therapy (TAT) and how does it work?\",\"answer\":\"TAT delivers alpha-emitting radionuclides to cancer tissue through chemical affinity or active targeting. High local energy deposition within a short tissue range enables precise treatment.\"},{\"question\":\"What main challenges affect TAT performance in vivo?\",\"answer\":\"Competing ions can cause transmetalation of the parent radionuclide, and decay daughters can relocate due to bond-breaking recoil energy. These processes influence radionuclide retention and the effective dose to cancer cells.\"},{\"question\":\"How did PLGA nanoparticles change delivery of actinium-225 in this study?\",\"answer\":\"PLGA encapsulation of [225Ac]Ac3+ and the chelated [225Ac]AcBLPhen reduced release and increased delivery to murine and human breast cancer cells. This led to higher cell death than free [225Ac]Ac3+ in solution.\"}]","Development of 225Ac-doped Biocompatible Nanoparticles for Targeted Alpha Therapy | PDF",1790014596,43,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35524c9841e244879ec3ecf0369de6d7.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/47366859bdef86bff7d2fae35beb2352.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b0e998877ec3c69586d27d7c8485c0ec.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c7c160e1cf2ae7fd85c3c63c42934b77.webp",980,1301]